Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 165Breast Neoplasms 163Carcinoma, Non-Small-Cell Lung 143Colorectal Neoplasms 101Prostatic Neoplasms 99Lung Neoplasms 86Ovarian Neoplasms 78Neoplasm Metastasis 72Multiple Myeloma 71Pancreatic Neoplasms 67Leukemia, Myeloid, Acute 59Endometrial Neoplasms 47Squamous Cell Carcinoma of Head and Neck 44Lymphoma 42Stomach Neoplasms 41Recurrence 40Melanoma 39Glioblastoma 39Carcinoma, Renal Cell 39Brain Neoplasms 39Carcinoma, Hepatocellular 38Urinary Bladder Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 37Lymphoma, Non-Hodgkin 34Leukemia, Lymphocytic, Chronic, B-Cell 34Hematologic Neoplasms 34Glioma 34Sarcoma 33Esophageal Neoplasms 31Small Cell Lung Carcinoma 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × HER2-positive Advanced Breast Cancer × 30 days × Clear all
NCT07047365 2026-06-03

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Recruiting
416 enrolled
Breast

HER2-positive Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡